Cynaptec Pharmaceuticals
Cambridge, United States· Est.
Biotech developing patented oral psilocin analogues for unmet neurological and psychiatric needs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $6M
AI Company Overview
Biotech developing patented oral psilocin analogues for unmet neurological and psychiatric needs.
NeurologyPsychiatry
Technology Platform
Patented oral stable analog of psilocin (Conjugated Psiloc™) that enhances bioavailability and therapeutic efficacy for CNS indications.
Opportunities
First‑to‑market oral psilocin analog for chronic cluster headache and potential expansion into substance‑use disorder therapies.
Risk Factors
Regulatory pathways for psychedelic analogues remain uncertain; pre‑clinical efficacy may not translate to human trials.
Competitive Landscape
Competes with other psychedelic biotech firms (e.g., COMPASS Pathways, MindMed) but differentiates via an oral, stable formulation that may simplify dosing and improve adherence.